FDA advisors strongly back new Alzheimer’s drug, despite risks and limitations
(By Jon Hamilton for NPR) Advisors to the Food and Drug Administration have recommended unanimously that the agency approve the
Read More
Donanemab
Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect
(By Madhav Thambisetty for STAT) Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover
Read MoreNew Alzheimer’s Drug Raises Hopes — Along With Questions
(By Judith Graham for KFF Health News) The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and
Read MoreThe Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
(By Arthur Allen for KFF Health News) The first drug purporting to slow the advance of Alzheimer’s disease is likely
Read MoreAn experimental Alzheimer’s drug outperforms one just approved by the FDA
(By Jon Hamilton for NPR) Patients in the early stages of Alzheimer’s may soon have a new option to stave
Read MoreEli Lilly says an experimental drug slows Alzheimer’s worsening
(Source -The Associated Press published May 4, 2023 by NPR) WASHINGTON — Eli Lilly and Co. said Wednesday its experimental
Read MoreMedicare to cover new Alzheimer’s drugs, Eli Lilly says
(By Jakob Emerson for Becker’s Hospital Review) Eli Lilly is expecting CMS to reverse course on its Medicare coverage policies
Read More